MARKET

EVOK

EVOK

Evoke Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.000
-0.110
-3.54%
Opening 13:53 02/26 EST
OPEN
3.190
PREV CLOSE
3.110
HIGH
3.190
LOW
2.900
VOLUME
320.49K
TURNOVER
--
52 WEEK HIGH
6.06
52 WEEK LOW
0.7900
MARKET CAP
94.00M
P/E (TTM)
-6.1000
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Gastroparesis Treatment Market is expected to reach around USD 5,323.62 million with at a 3.8% CAGR by 2023 | COVID-19 Analysis, Application, Growth, Business Opportunity, Segments and Revenue
Feb 24, 2021 (Heraldkeepers) -- Gastroparesis Treatment Market Overview: The global gastroparesis treatment market is predicted to touch USD 5,323.62 million...
Heraldkeepers · 1d ago
Evoke Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares
Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, announced today the completion of its follow-on offering of 5,750,000 shares of its common stock, including 750,00...
GlobeNewswire · 01/20 13:30
Evoke Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares
SOLANA BEACH, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, announced today the completion of its follow-on offering o...
GlobeNewswire · 01/20 13:30
Evoke Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares
SOLANA BEACH, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, announced today the completion of its follow-on offering o...
GlobeNewswire · 01/20 13:30
Evoke Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares
SOLANA BEACH, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, announced today the completion of its follow-on offering o...
GlobeNewswire · 01/20 13:30
Evoke Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares
GlobeNewswire · 01/20 13:30
Fiat Chrysler Automobiles, Vipshop Holdings leads the premarket losers' pack
Volt Information Sciences (VOLT) -17% erasing yesterday's gains post Q4 results.Live Ventures (LIVE) -12% erasing yesterday's gains post FY results.Takung Art (TKAT) -11%.Nano Dimension (NNDM) -10% after prices $332.5M direct offering.Viveve Medical (VIVE) -10% after pricing of upsized $24M
Seekingalpha · 01/14 13:48
The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 13)
Benzinga · 01/14 12:56
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EVOK. Analyze the recent business situations of Evoke Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EVOK stock price target is 9.50 with a high estimate of 10.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 41
Institutional Holdings: 3.08M
% Owned: 9.82%
Shares Outstanding: 31.33M
TypeInstitutionsShares
Increased
10
703.32K
New
10
70.31K
Decreased
5
20.71K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.70%
Pharmaceuticals & Medical Research
-0.51%
Key Executives
Chairman/Co-Founder/Director
Cam Garner
Chief Executive Officer/Founder/Director
David Gonyer
Executive Vice President/Treasurer/Secretary
Matthew D'Onofrio
Other
Marilyn Carlson
Director
Todd Brady
Director
Ann Rhoads
Director
Ken Widder
Director
Kenneth Widder
  • Dividends
  • Splits
  • Insider Activity
No Data
About EVOK
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.

Webull offers kinds of Evoke Pharma Inc stock information, including NASDAQ:EVOK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVOK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EVOK stock methods without spending real money on the virtual paper trading platform.